Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 18, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA, Nov. 14, 2019 /CNW/ - ProMIS...
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, Nov. 13, 2019 /CNW/ - ProMIS Neurosciences, Inc. ("ProMIS" or the "Company") (TSX: PMN;...
Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta in narrated overview TORONTO and CAMBRIDGE, MA, Nov. 7, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX:...
New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs TORONTO and CAMBRIDGE, MA, Oct. 24, 2019 /CNW/ - ProMIS Neurosciences, Inc....
Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases TORONTO and CAMBRIDGE, MA, Oct. 23, 2019 /CNW/ - ProMIS...
Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model TORONTO and CAMBRIDGE, MA, Oct. 17, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB:...
Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy TORONTO and CAMBRIDGE, MA, Oct. 8, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX:...
TORONTO and CAMBRIDGE, MA, Sept. 16, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...
TORONTO and CAMBRIDGE, MA, Aug. 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /CNW/ - ProMIS...
ProMIS' shareholders show overwhelming support for all resolutions TORONTO and CAMBRIDGE, MA, July 24, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...
Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS TORONTO and CAMBRIDGE, MA, July 18, 2019 /CNW/ - ProMIS...
Abstracts selected for oral and poster presentation TORONTO and CAMBRIDGE, MA, July 10, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the...
Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease TORONTO and CAMBRIDGE, MA,...
Data presented at Keystone Symposium on Neurodegenerative Diseases TORONTO and CAMBRIDGE, MA, June 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...
Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer TORONTO and CAMBRIDGE, MA, June 19, 2019 /CNW/ - ProMIS Neurosciences,...
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers TORONTO and CAMBRIDGE, MA, June...
TORONTO and CAMBRIDGE, MA, May 29, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...
Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease TORONTO and CAMBRIDGE, MA, May 28, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a ...
Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer's and Parkinson's diseases and ALS TORONTO and CAMBRIDGE, MA, May 14, 2019...
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, April 23, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...
Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS TORONTO and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.